Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04288271 · ClinicalTrials.gov registry record · NA
Teen Adherence in KidnEy Transplant Improving Tracking To Optimize Outcomes - Stage 3
A NA study, sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre.
- Completed
- Registry status
- NA
- Development phase
- 96
- Enrollment target
NCT04288271: Completed NA study, sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre.
NCT04288271 is a NA study that has completed, run by McGill University Health Centre/Research Institute of the McGill University Health Centre. The registered enrollment target is 96 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04288271, a NA study, has completed, sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre.
- COMPLETED
- Registry status
- NA
- Development phase
- 96 participants
- Enrollment target
Study Summary
Medication non-adherence is a major problem in kidney transplant recipients; young people 12-24 years of age are at particularly high risk for non-adherence and graft failure compared to young children and adults. Given that poor medication contributes greatly to graft failure, clinically feasible and effective interventions are urgently needed to improve adherence, survival, and quality of life in this population. The broad aim of this prospective, 3-stage, sequential study is to improve medication adherence in adolescent kidney transplant recipients by: 1) adapting the successful Teen Adherence in Kidney transplant Effectiveness of Intervention Trial (TAKE-IT) intervention for use in 'real world' clinical care, 2) designing and testing a new portable electronic pillbox and companion tracking website interface, and 3) preliminary testing of the adapted intervention.
Primary Outcome
percentage of prescribed doses taken each day (as measured by electronic monitoring). The daily taking adherence score could take a value of 0%, 50%, or 100% for patients on twice-daily dosing, and 0% or 100% for patients on once-daily dosing. Each patient will have a taking adherence score for every day of observation (repeated measures). On days that the pillbox was not in use due to technical problems or participant non-use, no score will be given. To summarize adherence for each arm, the tot
Interventions
- BEHAVIORAL Adherence Intervention
- OTHER Healthy living education intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2022-02-04 |
| Est. Completion | 2023-06-30 |
| Phase | NA |
Sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre9 total trials
What the finished NCT04288271 record still lists
NCT04288271 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 96 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 2 interventions - of which Adherence Intervention is the first listed.
NCT04288271 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04288271 about?
NCT04288271 is a clinical study titled "Teen Adherence in KidnEy Transplant Improving Tracking To Optimize Outcomes - Stage 3". Medication non-adherence is a major problem in kidney transplant recipients; young people 12-24 years of age are at particularly high risk for non-adherence and graft failure compared to young children and adults. Given that poor medication contributes greatly to graft failure, clinically feasible a...
What is the current status of trial NCT04288271?
This trial is currently completed. It is a NA study. The enrollment target is 96 participants. The study started on 2022-02-04. Estimated completion is 2023-06-30.
What interventions are being tested in trial NCT04288271?
The interventions under investigation include: Adherence Intervention (BEHAVIORAL), Healthy living education intervention (OTHER).
Who is sponsoring clinical trial NCT04288271?
This trial is sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04288271's enrollment target sits among peer trials
96 925th of 2000 higher than 1,070 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03401762 · 96 participants · NA
Wearable MCI to Reduce Muscle Co-activation in Acute and Chronic Stroke
- NCT03471260 · 96 participants · Phase 1
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- NCT03549559 · 96 participants · NA
Imaging Histone Deacetylase in the Heart
- NCT03841058 · 96 participants · Phase 2
Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI